{
  "guidances": [
    {
      "title": "Antipsychotic Drugs: Full and Abbreviated New Drug Applications",
      "date": "2020-09-15",
      "type": "drug",
      "drugTerms": [
        "olanzapine",
        "risperidone",
        "quetiapine",
        "aripiprazole",
        "antipsychotic"
      ],
      "classTerms": [
        "psycholeptics",
        "antipsychotics"
      ],
      "url": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/antipsychotic-drugs-full-and-abbreviated-new-drug-applications",
      "recommendations": [
        "Two adequate and well-controlled trials generally required",
        "Primary endpoint should demonstrate improvement in symptoms using validated scale",
        "Trials should include placebo control arm",
        "Minimum 6-week treatment duration for acute trials",
        "Long-term safety data (minimum 6 months) required for maintenance indications"
      ],
      "patientRecommendations": {
        "phase1": "20-40 healthy volunteers",
        "phase2": "100-300 patients",
        "phase3": "1000-3000 patients",
        "specialPopulations": "Include elderly patients with careful monitoring"
      }
    },
    {
      "title": "Antidepressant Drug Products: Full and Abbreviated ANDAs",
      "date": "2022-06-30",
      "type": "drug",
      "drugTerms": [
        "fluoxetine",
        "sertraline",
        "paroxetine",
        "citalopram",
        "antidepressant",
        "ssri"
      ],
      "classTerms": [
        "psychoanaleptics",
        "antidepressants"
      ],
      "url": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/antidepressant-drug-products-full-and-abbreviated-andas",
      "recommendations": [
        "Two adequate and well-controlled trials generally required",
        "Primary endpoint should demonstrate improvement in symptoms using validated scale",
        "Trials should include placebo control arm",
        "Minimum 8-week treatment duration for acute trials",
        "Long-term safety data (minimum10-12 months) required for maintenance indications"
      ],
      "patientRecommendations": {
        "phase1": "20-50 healthy volunteers",
        "phase2": "100-300 patients",
        "phase3": "1000-3000 patients",
        "specialPopulations": "Include adolescent and elderly populations in separate studies"
      }
    },
    {
      "title": "Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention",
      "date": "2023-02-15",
      "type": "drug",
      "drugTerms": [
        "metformin",
        "insulin",
        "glipizide",
        "sitagliptin",
        "antidiabetic"
      ],
      "classTerms": [
        "antidiabetic",
        "blood glucose lowering drugs"
      ],
      "url": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/diabetes-mellitus-developing-drugs-and-therapeutic-biologics-treatment-and-prevention",
      "recommendations": [
        "HbA1c reduction as primary endpoint",
        "Minimum 6-month controlled trial data",
        "Cardiovascular outcomes assessment required",
        "Include patients with renal impairment",
        "Hypoglycemia monitoring requirements"
      ],
      "patientRecommendations": {
        "phase1": "20-80 healthy volunteers and patients",
        "phase2": "200-500 patients",
        "phase3": "2000-5000 patients",
        "specialPopulations": "Include patients with renal impairment and cardiovascular risk factors"
      }
    },
    {
      "title": "Hypertension: Developing Fixed-Combination Drug Products for Treatment",
      "date": "2022-01-20",
      "type": "drug",
      "drugTerms": [
        "amlodipine",
        "lisinopril",
        "losartan",
        "valsartan",
        "antihypertensive"
      ],
      "classTerms": [
        "antihypertensives",
        "calcium channel blockers",
        "ace inhibitors"
      ],
      "url": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/hypertension-developing-fixed-combination-drug-products-treatment",
      "recommendations": [
        "Blood pressure reduction as primary endpoint",
        "Factorial design studies for combination products",
        "24-hour ambulatory blood pressure monitoring",
        "Minimum 8-week treatment duration",
        "Assessment of orthostatic hypotension"
      ],
      "patientRecommendations": {
        "phase1": "20-60 healthy volunteers and patients",
        "phase2": "100-300 patients",
        "phase3": "1000-3000 patients",
        "specialPopulations": "Include elderly patients and those with renal impairment"
      }
    },
    {
      "title": "Analgesic Indications: Developing Drug and Biological Products",
      "date": "2023-05-10",
      "type": "drug",
      "drugTerms": [
        "ibuprofen",
        "naproxen",
        "celecoxib",
        "diclofenac",
        "analgesic"
      ],
      "classTerms": [
        "analgesics",
        "nsaids",
        "anti-inflammatory"
      ],
      "url": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/analgesic-indications-developing-drug-and-biological-products",
      "recommendations": [
        "Pain intensity as primary endpoint using validated scale",
        "Enriched enrollment study designs",
        "Multiple-dose studies required",
        "Assessment of onset and duration of effect",
        "Cardiovascular risk assessment for NSAIDs"
      ],
      "patientRecommendations": {
        "phase1": "20-60 healthy volunteers",
        "phase2": "100-300 patients",
        "phase3": "800-2000 patients",
        "specialPopulations": "Include elderly patients and assess renal and hepatic effects"
      }
    },
    {
      "title": "Drug Development and Drug Interactions: Regulatory Considerations",
      "date": "2023-01-05",
      "type": "general",
      "drugTerms": [],
      "classTerms": [],
      "url": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-development-and-drug-interactions-regulatory-considerations",
      "recommendations": [
        "In vitro drug metabolism and transport studies",
        "Clinical drug-drug interaction studies",
        "Pharmacokinetic assessments",
        "Model-informed approaches for clinical trials",
        "Drug interaction labeling requirements"
      ],
      "patientRecommendations": {
        "phase1": "Depends on study design",
        "phase2": "Dedicated studies or subset analysis",
        "phase3": "Population pharmacokinetic analysis"
      }
    },
    {
      "title": "Guideline for Good Clinical Practice",
      "date": "2022-12-15",
      "type": "general",
      "drugTerms": [],
      "classTerms": [],
      "url": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guideline-good-clinical-practice",
      "recommendations": [
        "Ethical principles based on Declaration of Helsinki",
        "Institutional Review Board/Independent Ethics Committee requirements",
        "Informed consent procedures",
        "Safety reporting requirements",
        "Protocol development and amendments"
      ],
      "patientRecommendations": {
        "phase1": "Careful monitoring of first-in-human studies",
        "phase2": "Adequate safety monitoring",
        "phase3": "Representative patient population",
        "specialPopulations": "Additional safeguards for vulnerable populations"
      }
    }
  ]
}